Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
(technical difficulty)
Hoang, I'm the President and Chief Executive Officer of Marker Therapeutics. It's our great pleasure as a company to be able to present here today and tell you a little bit about what we have been doing as a company. So we should have our presentation projected momentarily here. Let me just say that we're a public company, and so I encourage you to refer to our public filings for a comprehensive list of risk factors as we will be making forward-looking statements today.
So Marker Therapeutics is, I think, a very, very different cell therapy company from most of the cell therapy companies that are advancing products in immuno-oncology today. In that what we are creating is a multi-antigen specific product that targets not only a single epitope of a single-target antigen, but potentially multiple target epitopes. In fact, our product seeks to create an omni epitope product across up to 5 tumor-associated antigens. In fact, our current products average around 4,000 different T cell clonotypes.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
